171 related articles for article (PubMed ID: 36730368)
1. Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
Bahlinger V; Hartmann A; Eckstein M
Adv Anat Pathol; 2023 May; 30(3):203-210. PubMed ID: 36730368
[TBL] [Abstract][Full Text] [Related]
2. [Immunological biomarker research in uro-oncology-using the example of urothelial cancer].
Eckstein M
Urologie; 2022 Jul; 61(7):734-738. PubMed ID: 35925244
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
5. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
6. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers.
Mohanty SK; Mishra SK; Amin MB; Agaimy A; Fuchs F
Adv Anat Pathol; 2023 May; 30(3):174-194. PubMed ID: 37037418
[TBL] [Abstract][Full Text] [Related]
7. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Mann SA; Lopez-Beltran A; Massari F; Pili R; Fiorentino M; Koch MO; Kaimakliotis HZ; Wang L; Scarpelli M; Ciccarese C; Moch H; Montironi R; Cheng L
Curr Drug Metab; 2017 Oct; 18(8):700-711. PubMed ID: 28524003
[TBL] [Abstract][Full Text] [Related]
8. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
9. Landscape of Immunotherapy in Genitourinary Malignancies.
Ravindranathan D; Alhalabi O; Rafei H; Shah AY; Bilen MA
Adv Exp Med Biol; 2021; 1342():143-192. PubMed ID: 34972965
[TBL] [Abstract][Full Text] [Related]
10. Current Landscape of Immunotherapy in Genitourinary Malignancies.
Alhalabi O; Rafei H; Bilen MA; Shah AY
Adv Exp Med Biol; 2020; 1244():107-147. PubMed ID: 32301013
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Davick JJ; Frierson HF; Smolkin M; Gru AA
Hum Pathol; 2018 Nov; 81():184-191. PubMed ID: 29969606
[TBL] [Abstract][Full Text] [Related]
13. Optimal Selection of Patients with Genitourinary Cancers for Anti-PD1/PD-L1 Treatment with a Focus on Urothelial and Renal Cell Carcinoma.
Zeuschner P; Junker K
Eur Urol Focus; 2022 Jul; 8(4):907-909. PubMed ID: 35918269
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Zhu J; Armstrong AJ; Friedlander TW; Kim W; Pal SK; George DJ; Zhang T
J Immunother Cancer; 2018 Jan; 6(1):4. PubMed ID: 29368638
[TBL] [Abstract][Full Text] [Related]
15. Use of immunotherapy in clinical management of genitourinary cancers - a review.
Mar N; Uchio E; Kalebasty AR
Cancer Treat Res Commun; 2022; 31():100564. PubMed ID: 35472699
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A; Plimack ER
Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
[TBL] [Abstract][Full Text] [Related]
17. Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors in Head and Neck Cancer.
Taverna C; Franchi A
Adv Anat Pathol; 2023 May; 30(3):167-173. PubMed ID: 36175939
[TBL] [Abstract][Full Text] [Related]
18. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
Dallos MC; Drake CG
Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma.
Tang G; Liu J; Qi L; Li Y
Br J Clin Pharmacol; 2023 Jan; 89(1):93-113. PubMed ID: 35997657
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for genitourinary tumors.
Nakayama T; Kitano S
Int J Urol; 2019 Mar; 26(3):326-333. PubMed ID: 30710374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]